ERBB2 and breast carcinoma: Given the overall improved outlook and better survival for patients with HER2-positive breast cancer, there is a real need for further targeted therapies once patients have become trastuzumab resistant, and in particular, for those with CNS disease for whom treatment options are even more limited.